Abstract
With the widely usage of proteasome inhibitors, immunomodulating agents, monoclonal antibodies and autologous stem cell transplantation in the first line, most of multiple myeloma(MM) patients achieved high response rate and prolonged the survival period, but most of MM patients will relapse eventually. There are a lot of unmet needs for the management of relapse and refractory myeloma (RRMM). Although there are several guidelines for the diagnosis and treatment of RRMM, but doctors often find some controversies in clinical practice. The controversies will be discussed in this paper expected to guide the practice of younger doctors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
